1.
J Invest Dermatol
; 129(9): 2299-302, 2009 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19225543
Assuntos
Psoríase/tratamento farmacológico , Pirimidinas/uso terapêutico , Pirróis/uso terapêutico , Adulto , Biópsia , Relação Dose-Resposta a Droga , Método Duplo-Cego , Humanos , Pessoa de Meia-Idade , Piperidinas , Psoríase/imunologia , Psoríase/patologia , Pirimidinas/efeitos adversos , Pirróis/efeitos adversos
2.
Science
; 302(5646): 875-8, 2003 Oct 31.
Artigo
em Inglês
| MEDLINE
| ID: mdl-14593182
RESUMO
Because of its requirement for signaling by multiple cytokines, Janus kinase 3 (JAK3) is an excellent target for clinical immunosuppression. We report the development of a specific, orally active inhibitor of JAK3, CP-690,550, that significantly prolonged survival in a murine model of heart transplantation and in cynomolgus monkeys receiving kidney transplants. CP-690,550 treatment was not associated with hypertension, hyperlipidemia, or lymphoproliferative disease. On the basis of these preclinical results, we believe JAK3 blockade by CP-690,550 has potential for therapeutically desirable immunosuppression in human organ transplantation and in other clinical settings.